| Name | Title | Contact Details |
|---|
RPS Pharmacy is an affiliate of Millenium Pharmaceuticals and as such, we are committed to quality healthcare with an honest approach that values patient privacy and security. All information provided to us is legally protected under the doctor-patient
Cactus Communications Pvt. is a Trevose, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1999, Bioheart, Inc. is committed to the development of effective cell technologies to treat cardiovascular diseases.
ServRx is a leading national workers` compensation prescription drug claims processing company. With a strong backbone of proprietary IT and decades of experience in the workers` compensation space, ServRx serves a rapidly growing share of community and independent pharmacies. Across America, each pharmacy client is as unique as the injured workers they treat. ServRx prides itself on creating customized solutions to meet the needs of our diverse client-base. Rural mom-and-pop pharmacies, regional chains, specialty pharmacies, and large pharmacy management firms alike have turned to ServRx to handle the unique workflow and cash-flow challenges posed by workers` compensation. A winning mix of experience, technology, and economies of scale allows ServRx to promise its clients superior handling of their workers` compensation claims. Whether they process one pharmacy claim per week, or hundreds per day, ServRx clients have something in common: peace of mind and increased profitability.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.